Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have earned an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $29.50.

Several analysts have weighed in on ROIV shares. The Goldman Sachs Group boosted their price target on shares of Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Wednesday, March 4th. Weiss Ratings lowered Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, February 9th. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Finally, HC Wainwright lifted their price target on Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th.

Roivant Sciences Stock Down 0.4%

Shares of ROIV stock opened at $27.70 on Friday. The business has a 50-day moving average price of $25.92 and a two-hundred day moving average price of $21.19. Roivant Sciences has a 12-month low of $8.73 and a 12-month high of $30.33. The firm has a market cap of $19.82 billion, a P/E ratio of -23.68 and a beta of 1.17.

Insider Buying and Selling at Roivant Sciences

In other news, Director Melissa B. Epperly sold 41,861 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $28.68, for a total transaction of $1,200,573.48. Following the completion of the sale, the director directly owned 15,804 shares in the company, valued at approximately $453,258.72. This represents a 72.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Daniel Allen Gold sold 375,784 shares of the firm’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $26.50, for a total value of $9,958,276.00. Following the completion of the sale, the director directly owned 15,127,329 shares in the company, valued at $400,874,218.50. The trade was a 2.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,794,685 shares of company stock worth $173,053,290 over the last ninety days. 10.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. Jones Financial Companies Lllp grew its position in shares of Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after buying an additional 1,148 shares during the last quarter. SBI Securities Co. Ltd. increased its stake in shares of Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after buying an additional 1,166 shares during the period. Allworth Financial LP raised its holdings in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after acquiring an additional 583 shares in the last quarter. Bessemer Group Inc. lifted its stake in Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the period. Finally, Kestra Advisory Services LLC purchased a new stake in Roivant Sciences in the fourth quarter worth $47,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.